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KEY FINDINGS 31 
 The disaccharide Galα1-3Galβ is the immunodominant saccharide in Leishmania cell surface and is the 32 
unique non-reducing terminal glycosphingolipids structure recognized by anti-α-Gal.  33 
 Sensitivity and specificity of all NGPs ranged from 62,2% to 78,4% and 58.3% to 96,7%, respectively.  34 




Oligosaccharides are broadly present on Leishmania cell surfaces. They can be useful for the leishmaniases 39 
diagnosis and also helpful in identifying new cell markers for the disease. The disaccharide Galα1-3Galβ is the 40 
immunodominant saccharide in Leishmania cell surface and is the unique non-reducing terminal 41 
glycosphingolipids structure recognized by anti-α-Gal. This study describes an enzyme-linked immunosorbent 42 
assay (ELISA) used to measure serum levels of anti-α-galactosyl (α-Gal) antibodies in patients with cutaneous 43 
leishmaniasis (CL). Optimal ELISA conditions were established and two neoglycoproteins (NGP) containing 44 
the Galα1-3Gal terminal fraction (Galα1-3Galβ1-4GlcNAc-HAS and Galα1-3Gal-HAS) and one Galα1-3Gal 45 
NGP analogue (Galα1-3Galβ1-3GlcNAc-HAS) were used as antigens. Means of anti-α-Gal antibody titres of 46 
CL patients were significantly higher (p<0.05) than the healthy individuals for all NGPs tested. Sensitivity and 47 
specificity of all NGPs ranged from 62,2% to 78,4% and 58.3% to 96,7%, respectively. In conclusion, the NGPs 48 
can be used for CL diagnosis.  49 
 50 












INTRODUTION  61 
 62 
The Leishmaniases complex are divided into three distinct forms of clinical presentation. The major 63 
factor that determines the development of each form of the disease is the specie of parasite associated with the 64 
host’s specific immune responses (not all those infected by the parasites will develop the disease). In the most 65 
common form of the disease, cutaneous leishmaniasis (CL), the parasites remain only at the site of the sand fly 66 
bite and cause localized long-term ulceration with no systemic symptoms. In some cases, inadequate treatment 67 
of a CL lesion may lead to later development of mucocutaneous leishmaniasis (ML). The third clinical form is 68 
visceral leishmaniasis (VL) that is the most pathogenic in which parasites migrate from the inoculation site to 69 
multiply in the host’s liver and spleen macrophages and bone marrow, causing immunosuppression and death if 70 
not treated (PEACOCK, 2007; CAMPOS et al., 2008; DAVID & CRAFT, 2009; BIFELD & CLOS, 2015; 71 
VAN DER AUWERA & DUJARDIN, 2015). The control of leishmaniases is presently a serious problem due to 72 
the high death rates involved and the economic losses resulting from morbidity. In addition, the disease is 73 
strongly linked to poverty in the tropical and subtropical areas and with ever increasing cases worldwide each 74 
year. Ninety-eight countries are officially considered endemic for leishmaniases and estimates show that more 75 
than 58.000 VL and 220.000 CL cases are notified per year. More than 90% of global VL cases occurring in six 76 
countries - India, Bangladesh, Sudan, South Sudan, Brazil and Ethiopia - and around 75% of global CL cases 77 
occurring in ten countries - Afghanistan, Algeria, Colombia, Brazil, Iran, Syria, Ethiopia, North Sudan, Costa 78 
Rica and Peru. (ALVAR et al., 2012; DE VRIES, REEDIJK & SCHALLIG, 2015).  79 
Rapid methods for the effective leishmaniases diagnosis and species identification are urgently 80 
needed, either by prevention and control of leishmaniases in endemic areas or treatment of infected patients. The 81 
definitive diagnosis of all suspected Leishmania infections should be performed in an association of clinical 82 
symptoms, and parasitological and immunologic findings. Several diagnostic methods have been described to 83 
detect the presence of the Leishmania parasites, with a huge variation in diagnostic accuracy, including direct 84 
parasitological examination by microscopy, histopathology and/or parasite culture, indirect testing by serology 85 
and molecular diagnostics. The demonstration of the presence of the parasite by parasitological diagnosis is still 86 
considered the gold standard in leishmaniases diagnosis because of its high specificity. However, the sensitivity 87 
of the direct examinations is low for the diagnosis of CL and ML, with a range from 15% to 70%, whilst in case 88 
of VL the sensitivity varies depending on the tissue used, with a range from 93% to 99% for spleen, 53% to 86% 89 
for bone marrow and 53% to 65% for lymph node aspirates. Moreover, parasite culture in the culture media is 90 
 
 
difficult, requires technical skills, is prone to contamination, and is time-consuming. As all other parasitological 91 
method for Leishmania detection, the parasite culture does not allow Leishmania species determination. The 92 
sensitivity of cultures depends on the parasite quantity, but is estimated to be between 60% and 85%. 93 
(BHARGAVA & SINGH, 2012; REZVAN, 2014; DE VRIES, REEDIJK & SCHALLIG, 2015; 94 
GEORGIADOU, MAKARITSIS & DALEKOS, 2015; PAIVA-CAVALCANTI et al., 2015).  95 
Alternative and complementary diagnosis techniques also include the evaluation of indirect 96 
parameters. The Montenegro skin test has been successfully used in the diagnosis of cutaneous and 97 
mucocutaneous forms of the disease. Its sensitivity range from 86.4%, but it is not very reliable for detecting the 98 
presence of parasites in recent lesions, in diffuse forms of disease and in immunosuppressed patients, as well as 99 
not differentiating between past and present infection (GOTO & LINDOSO, 2012; DE VRIES, REEDIJK & 100 
SCHALLIG, 2015; HANDLER et al., 2015; PAIVA-CAVALCANTI et al., 2015).  101 
Immunological diagnoses, another important indirect method for detecting leishmaniases, are based 102 
on the detection of either Leishmania antigens or anti-Leishmania antibodies in the host serum samples. The 103 
optimal test for serologic diagnosis is one that is easy to use, cheap to make and has both a high sensitivity and 104 
specificity. Most of the immunological techniques for the detection of anti-Leishmania antibodies have been 105 
based on the Enzyme-Linked Immunosorbent Assay (ELISA) technique and the sensitivity and specificity of 106 
this method depends on the antigen employed. Considering the variations of the individual immune responses to 107 
the infection, several antigens have been identified for potential use in the diagnosis of leishmaniases (GOTO & 108 
LINDOSO, 2012; MAIA et al., 2012; SÁNCHEZ-OVEJERO et al., 2016). 109 
Oligosaccharides are broadly present on cell surfaces arranged as glycan arrays, responsible for 110 
regulating the interaction between cells. They can be useful for disease diagnosis and also helpful in identifying 111 
new disease-causing microbial cell markers.  The interactions among pathogens and their host cells are guided 112 
by different cell-surface glycans and glycan binding receptors at each stage of the infectious process 113 
(FERNÁNDEZ-TEJADA et al., 2015). Glycoinositol phospholipids (GIPLs) are the main family of low 114 
molecular weight glycolipids synthesized by Leishmania parasites. It is expressed in abundance on promastigote 115 
and amastigote cell surfaces and is not linked to proteins, forming a protective surface revetment that provides 116 
essential host-parasite interactions. However, each parasite stage is already known to have a different 117 
glycoconjugate attached on its surface beyond GIPLs. Biochemical analyses reveal that, unlike amastigotes, the 118 
procyclic promastigotes surface coat expresses two other glycoconjugates which are less abundant than GIPLs 119 
and are responsible for protecting parasites from hydrolytic enzymes in the sandfly gut: 1) 120 
 
 
glycosylphosphatidylinositol (GPI) anchored to macromolecules such as metalloprotease and; 2) protein-free 121 
lipophosphoglycan complex (LPG), a GPI-anchored macromolecules underlying layer composed of densely, 122 
free-packed glycolipids. Altogether these molecules create an effective barrier which protects promastigotes 123 
from cell death processes like lysis mediated by complement system, oxygen radicals and hydrolases in the 124 
mammalian and insect host environments (ILGOUTZ et al., 2001; MUKHOPADHYAY et al., 2006; 125 
BARRETO-BERGTER et al., 2010; GALILI, 2013a).  126 
High levels of antibody produced against GIPLs have been reported in people infected with 127 
trypanosomatid parasites (ÁVILA et al., 1988; 1989; 1991; ALMEIDA et al., 1994). Remarkably, anti-α-Gal 128 
recognizes specifically the unique glycosphingolipids structures known as the GPI-anchored mucins in the 129 
trypomastigote stage of Trypanosoma spp (GALILI, 1993; MARCHER; GALILI, 2008; SCHOCKER et al., 130 
2016). However, the parasites escape through the antibodies’ action by penetrating tissues and continue to 131 
produce and release GIPLs and LPG with α-Gal epitopes, stimulating the immune system to continuously 132 
produce anti-α-Gal antibodies at high titres (GALILI, 2013a). Quantities of anti-α-Gal antibodies constantly 133 
produced can also represent a continuous immune response to Galα1-3 Gal structures found in various 134 
gastrointestinal bacteria, confirming the polyreactive nature of these antibodies in human serum (GALILI, 1984; 135 
GALILI et al., 1987; GALILI, 2013b). 136 
The major GIPLs found in these parasites’ cell membranes include tetraglycosylinositol, 137 
pentaglycosylinositol, and hexaglycosylphosphatidylinositol and sugar analysis of L. mexicana and L. 138 
braziliensis GIPLs revealed monosaccharide composition of Manose (Man), Galactose (Gal), Glucosamine 139 
(GlcN), and inositol (ÁVILA et al., 1991; MCCONVILLE & FERGUSON, 1993). 140 
Anti-α-Gal is the most abundant natural circulating human antibody and, since it binds specifically to 141 
the Galα1–3Gal glycosphingolipids (GALILI, 1993; MARCHER et al., 2008; SCHOCKER et al., 2016), it is 142 
assumed that the majority of the anti-α-Gal binding sites expressed in the cell membranes of many organisms 143 
have this non-reducing terminal structure (GALILI et al., 1988; GALILI, 1993; GALILI et al., 1995; GALILI, 144 
2013a, b). However, quantities of anti-α-Gal antibodies constantly produced can also represent a continuous 145 
immune response to Galα1-3 Gal structures found in various gastrointestinal bacteria (GALILI, 1984; GALILI 146 
et al., 1987; GALILI, 2013b), confirming the polyreactive nature of these antibodies in human serum 147 
(SATAPATHY et al., 1999).  148 
The α-Gal has the potential for many clinical uses once anti-Gal antibodies are widely produced in 149 
healthy humans and α-gal epitopes can be easily synthesized by several methods. This study describes an 150 
 
 
standardized enzyme-linked immunosorbent assay (ELISA) used to measure serum levels of anti-α-Gal 151 
antibodies in individuals with cutaneous leishmaniasis (CL) from different endemic regions in Brazil and 152 
compares them to those from healthy individuals living in the same endemic areas and non-endemic areas using 153 
different neoglycoproteins (NGPs) from the antigen. 154 
 155 
MATERIALS AND METHODS 156 
 157 
Sample collection  158 
 159 
A total of 149 serum samples from females and males of different age groups were collected from CL 160 
endemic and non-endemic regions in Brazil. The main inclusion criterion was the proven diagnosis of CL by 161 
parasite presence on the direct examination of lesion smears obtained from the edge of the active lesion with a 162 
punch biopsy tool and/or positivity in the parasite culturing. The samples were divided into seven groups (Table 163 
1): 1) H1 (23): healthy individuals from non-endemic areas; 2) H2 (37): healthy individuals from endemic areas; 164 
3) CL1 (12): CL patients with active lesion and no treatment; 4) CL2 (5): CL patients with active lesion under 165 
the treatment; 5) CL3 (13): CL patients that had finished treatment and were under observation for the 166 
subsequent 3 months; 6) OD (54): serum reagent patients for other diseases such as Hepatitis B and C, Syphilis 167 
and truly positive patients for Tuberculosis; 7) CD (5): serum reagent patients for Chagas disease.  168 
Individuals from H2 group were medically examined to discard any previous CL infection. CL 169 
patients were treated according to the Brazilian Healthy Ministry guideline, with meglumine antimoniate and 170 
amphotericin B. Patients with other diseases such as Chagas disease were also studied to evaluate the chance of 171 
cross-reactivity in these tests.  172 
Ethical approval was obtained from the Universidade Federal do Paraná Ethical Committee under 173 
number 684.244. 174 
 175 
Enzyme-linked immunosorbent assay (ELISA) 176 
 177 
To determine whether levels of anti-α-Gal antibodies in human serum, both non-infected and infected 178 
with CL and other diseases can identify Leishmania α-Gal epitopes, optimal ELISA conditions were established, 179 
such as dilutions of sera (1:100, 1:200, 1:400 and 1:800), conjugate (1:5,000, 1:10,000 and 1:20,000) and 180 
 
 
antigens (0.1 , 0.5 and 1 µg/well). Once the best condition was established, polystyrene microtiter plates with 96 181 
wells (NUNC C96 Immuno Plate Maxisorp Surface, Thermo Scientific) were coated overnight at 4°C with 100 182 
µL of 0,1 µg/well of two Galα1-3Gal neoglycoprotein series with 3-atom spacer (Galα1-3Galβ1-4GlcNAc 183 
conjugated with human albumin serum , identified as NGP 2334; and Galα1-3Gal conjugated with human 184 
albumin serum, identified as NGP2203 - Dextra Laboratories) and one Galα1-3Gal analogue neoglycoprotein 185 
with 3-atom spacer (Galα1-3Galβ1-3GlcNAc conjugated with human albumin serum, identified as NGP2333 - 186 
Dextra Laboratories), diluted in carbonate–bicarbonate buffer (pH 9.6). In addition, the β-Gal NGP β1-4-187 
Galactosyl-Galactose conjugated with bovine serum albumin and with 3-atom spacer (NGP 0204, Dextra 188 
Laboratories) was also included in the study as the “β-control” and soluble proteins from the crude extract from 189 
Leishmania (Viannia) braziliensis culture (strain MHOM/BR/84/LTB300) as a positive control. Human albumin 190 
serum was chosen for the generation of NGPs because of its absence of immunological reaction with human 191 
serum and its adequacy as a carrier protein.  192 
The following day, the plates were washed twice with 200 μL/well of washing solution (NaCl 0.9% + 193 
Tween 20 at 0.05%), then the wells were blocked with 120 µL of blocking solution (Pierce Protein - Free T20 – 194 
PBS Blocking Buffer, Thermo Scientific) for one hour at 37°C, and after were washed twice again with 200 195 
μL/well of washing solution. Immediately after, serum samples were diluted to 1:800 in a solution of PBS – 196 
0.25% casein + 0.5% Tween 20 and were added to their respective wells and incubated at 37 °C for one hour. 197 
Then the plates were washed four times with 200 μL/well of washing solution and polyclonal rabbit anti-human 198 
IgG HRP conjugate (1.3 g/L, Dako) was diluted to 1:5,000 and was added to each well for one hour at 37°C. 199 
Finally, the reaction was developed by adding 100 μL of SureBlue TMB™ Microwell Peroxidase Substrate to 200 
each well at room temperature for 15 minutes, avoiding light, and to interrupt the reaction 20 µL of a solution 201 
1:20 of H2SO4 was added. Plates were read in the Infinite F200 PRO multimode reader (Tecan) at 450 nm and 202 
values were expressed in absorbance. Each sample was measured in triplicate, including the “no serum” control 203 
for preventing the background from the secondary antibody (blank control), and the whole assay described 204 
above was performed in duplicate. The absorbance readings were performed subtracting the mean of blank 205 







Determination of α-Gal specific activity 211 
 212 
Based on Al-Salem et al. (2014) CBAG treatment protocol to determine the α-Gal specific activity, 213 
0.1 μg/well of each NGP previously tested, except for NGP 2204, were treated overnight at 28°C with 0.04 214 
U/well of α-galactosidase from green coffee beans (Sigma). After incubation, the plates were washed five times 215 
with washing solution and the ELISA was performed as described above. A pool of seven serums from CL1 and 216 
CL2 and 10 from H1 individuals was also used as positive and negative controls, respectively. 217 
 218 
Statistical analysis  219 
 220 
The homogeneity of variance analysis and the Kolmogorov-Smirnov test for the normal condition of 221 
variables evaluation were performed using the Statistica 7 and MedCalc 16.1 software, respectively. Once data 222 
showed non-parametric distribution, a Kruskal-Wallis one-way analysis with a Dunn post-test was performed to 223 
validate the significant difference among groups. The Mann-Whitney analysis was used to compare the means 224 
of each group between antigens and positive and negative controls. All non-parametric analyses were performed 225 
using GraphPad Prism 6 software, assuming the significant level of p<0.05. Finally, Receiver Operating 226 
Characteristics (ROC) curve were performed based on the logistic regression model, considering the 227 
classification of the samples (presence or absence of the disease) as a dependent variable and each antigen as an 228 
independent variable. Logistic regression model, ROC curve and sensitivity and specificity analyses were 229 
performed using R software (R CORE TEAM, Version 3.4.0, 2017) with auxiliary pROC system (Robin et al., 230 
2011) and a significant level of p<0.05 was adopted.  231 
 232 
RESULTS  233 
 234 
Enzyme-linked immunosorbent assay (ELISA) 235 
 236 
All serum samples collected were analysed on two occasions. First, absorbance values of samples 237 
from H1 and CL1 groups were used to perform the ROC curve analysis, sensitivity, specificity and odds ratio of 238 
all antigens. The results obtained were compared with the same parameters of the same sample groups for the 239 
positive control (Figure 1 and table 2). The cut-off values for CL were: 0,030 for NGP0204, 0,135 for L. 240 
 
 
braziliensis crude extract and NGP2333,   0,131 for NGP2203 and 0,550 for NGP 2334; whilst sensitivity and 241 
specificity ranged from 62,2% (NGP 2203) to 78,4% (L. braziliensis crude extract), and 58.3% (NGP 0204) to 242 
96,7% (NGP2334), respectively.  243 
The presence of Leishmania anti-α-Gal antibodies was determined by comparing anti-α-Gal levels in 244 
CL patients and healthy individuals living in the same endemic area, non-endemic area and individuals with 245 
other diseases (Table 3). It was found that means of anti-α-Gal antibody titres of only CL2 and CL3 groups were 246 
significantly higher (p<0.05) than the H1 group for NGP 2234 and NGP 2333. For NGP 2203, all CL groups 247 
presented significantly higher means of antibody levels (p<0.05) compared to H1 group. No cross-reaction 248 
between the NGPs and antibodies from patients with other diseases was detected, except for the Chagas disease 249 
(CD), since the etiological agent of this disease is another trypanosomatid parasite.  250 
When comparing each sera group for each antigen singly (Table 4), means of antibody titres of CL1 251 
group from all NGPs showed no significant difference compared to the same group from L. braziliensis. 252 
However, means of antibody titres of CL2 from NGP 2334 and CL3 groups from all NGPs showed higher 253 
difference compared to the same groups L. braziliensis.  Also, means of antibody titres of CL3 and CD groups 254 
from NGP 0204 showed lower significant differences compared to all NGPs, indicating that the β-Gal NGP is 255 
not able to be detected by antibodies of CD patients and/or CL patients after treatment.  256 
 257 
Determination of α-Gal specific activity 258 
 259 
To determine the specific immunogenic activity of the α-Gal residues, all NGPs, except for NGP 260 
2204, were treated with α-galactosidase enzyme from green coffee beans, which specifically unlinks Galα1-261 
3Gal into two parts - Galα1 and 3Gal – and, consequently, abrogates the recognition of α-Gal epitope by anti-α-262 
Gal antibodies (Figure 2). Although it is clear there is still an antigen-antibody reaction detected in the assay 263 
performed with the presence of the α-galactosidase enzyme, compared to the controls, patients from the 264 
CL1/CL2 and CL3 groups used in enzymatic treatment assay with NGP 2334 showed a 2- and 3-fold decrease 265 
in the antibody titres than positive control, respectively. The same result was found for the other antigens: a 2.5- 266 
and 4-fold decrease in the antibody titres for CL1/CL2 and CL3 groups for NGP 2333 antigen, respectively; and 267 
2.5- and 4-fold for the CL1/CL2 and CL3 groups NGP 2203 antigen, respectively. H2 and H1 groups used in 268 
enzymatic treatment also presented a decrease in the antibody titres when compared to the positive and negative 269 





Different NGP sequences were able to be better detected by anti-α-Gal antibodies from CL patients 273 
under treatment and those that were under observation post-treatment compared to active CL patients, pointing 274 
out that the increase in the anti-α-Gal levels could be used as a potential biomarker for detection the presence of 275 
CL. However, means of antibody titres of CL patients with active lesions showed no difference compared to the 276 
same group for positive control, meaning that all NGPs tested were able to detect anti-Leishmania antibody 277 
levels in CL patients with active lesions at the same level of the crude extract from L. braziliensis. Previous 278 
studies also suggest that sera from patients with active Leishmania lesions and cured individuals were able to 279 
recognize α-Gal epitopes (ÁVILA et al., 1989; 1990; AL-SALEM et al., 2014).  280 
When Leishmania spread through the mammalian host cells, the parasites are rarely exposed directly 281 
to the humoral immune response and the presence of antibodies is induced by the complement system when in 282 
contact with the Leishmania membrane (BIFELD et al., 2015). Levels of anti-α-Gal antibodies increase as the 283 
disease progresses (ÁVILA et al., 1990), also giving support in explaining why few truly infected individuals 284 
had presented anti-α-Gal levels below the cut-off line. Either total parasite clearance can takes several years to 285 
complete or the treatment could allow a parasite cell lysis, releasing more α-Gal epitopes to the host immune 286 
system.  287 
No cross-reaction between the NGPs and antibodies from patients with other diseases was detected, 288 
except for the Chagas disease, since the etiological agent of this disease is another trypanosomatid parasite. 289 
Ashmus et al. (2013) also showed that chagasic anti-α-Gal antibodies strongly recognize saccharides containing 290 
the non-reducing terminal disaccharide Galα1-3Galβ moiety.  291 
The presence of different antibodies binding to similar epitopes, either in CL or patients with chronic 292 
Trypanosoma infections can indicate the strong presence of highly immunogenic oligosaccharide antigens 293 
linked to phosphatidylinositol in trypanosomatid parasites (ÁVILA et al., 1988; 1991). Anti-α-Gal antibodies 294 
specifically interact with glycoconjugates that have Galα1-3Galβ1-4GlcNAc residues but do not interact with 295 
Galα1-4Galβ1-4GlcNAc, β-galactosyl, or glycoconjugates with other carbohydrate residues. The α-Gal binding 296 
site has a size corresponding to the free trisaccharide Galα1-3Galβ1-4GlcNAcα- and it exhibits seven-fold 297 
higher in affinity of human anti-α-Gal than that to the disaccharide Galα1-3Gal, and much more strongly than α-298 
Gal alone (GALILI et al., 1985; GALILI, 1989; 2013b; OBUKHOVA et al., 2007; SCHOCKER et al., 2016). A 299 
decrease of antibody titres from CL patients was noticed when the α-Gal residues specific immunogenic activity 300 
 
 
protocol was applied. The same results were observed by Galili et al. (1984) and Ávila et al. (1988; 1989; 1990; 301 
1991), suggesting that GPIs oligosaccharide chains have only terminal α-galactose residues. It can lead to the 302 
conclusion that the disaccharide Galα1-3Galβ is the immunodominant saccharide in Leishmania cell surface and 303 
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Table 1. Demographic data of the study cohort. H1: healthy individuals from non-endemic areas, H2: healthy 478 
individuals from endemic areas, CL1: CL patients with active lesion and no treatment, CL2: CL patients with 479 
active lesion under the treatment, CL3: CL patients that had finished treatment and were under observation for 480 
the subsequent 3 months, OD: serum reagent patients for other diseases such as Hepatitis B and C, Syphilis 481 
(diagnosis performed by a blood bank) and truly positive patients for Tuberculosis , CD: serum reagent patients 482 





At the moment of the blood 
collection, the patient was... 
Group H1 
NCNE 01 healthy individuals from non-endemic area No treatment 
NCNE 03 healthy individuals from non-endemic area No treatment 
NCNE 04 healthy individuals from non-endemic area No treatment 
NCNE 05 healthy individuals from non-endemic area No treatment 
NCNE 06 healthy individuals from non-endemic area No treatment 
NCNE 07 healthy individuals from non-endemic area No treatment 
NCNE 08 healthy individuals from non-endemic area No treatment 
NCNE 09 healthy individuals from non-endemic area No treatment 
NCNE 10 healthy individuals from non-endemic area No treatment 
NCNE 12 healthy individuals from non-endemic area No treatment 
NCNE 13 healthy individuals from non-endemic area No treatment 
NCNE 14 healthy individuals from non-endemic area No treatment 
NCNE 15 healthy individuals from non-endemic area No treatment 
NCNE 16 healthy individuals from non-endemic area No treatment 
NCNE 17 healthy individuals from non-endemic area No treatment 
NCNE 18 healthy individuals from non-endemic area No treatment 
NCNE 19 healthy individuals from non-endemic area No treatment 
NCNE 20 healthy individuals from non-endemic area No treatment 
NCNE 21 healthy individuals from non-endemic area No treatment 
NCNE 22 healthy individuals from non-endemic area No treatment 
NCNE 23 healthy individuals from non-endemic area No treatment 
NCNE 24 healthy individuals from non-endemic area No treatment 
NCNE 25 healthy individuals from non-endemic area No treatment 
Group H2 
NCE 01 healthy individuals from endemic area 
Having treatment for high blood 
pressure and rheumatism 
NCE 02 healthy individuals from endemic area 
Having treatment for high blood 
pressure and myalgia 
NCE 03 healthy individuals from endemic area No treatment 
NCE 04 healthy individuals from endemic area No treatment 
NCE 05 healthy individuals from endemic area No treatment 
NCE 07 healthy individuals from endemic area 








At the moment of the blood 
collection, the patient was... 
Group H2 
NCE 08 healthy individuals from endemic area No treatment 
NCE 09 healthy individuals from endemic area No treatment 
NCE 10 healthy individuals from endemic area No treatment 
NCE 11 healthy individuals from endemic area 
Having treatment for high blood 
pressure 
NCE 12 healthy individuals from endemic area No treatment 
NCE 13 healthy individuals from endemic area 
Having treatment for high blood 
pressure 
NCE 14 healthy individuals from endemic area No treatment 
NCE 15 healthy individuals from endemic area No treatment 
NCE 16 healthy individuals from endemic area No treatment 
NCE 17 healthy individuals from endemic area No treatment 
NCE 18 healthy individuals from endemic area 
Having treatment for 
hypercholesterolemia (sinvastatine) 
NCE 19 healthy individuals from endemic area No treatment 
NCE 20 healthy individuals from endemic area No treatment 
NCE 21 healthy individuals from endemic area 
Having treatment for high blood 
pressure 
NCE 22 healthy individuals from endemic area Having treatment for rheumatism 
NCE 23 healthy individuals from endemic area No treatment 
NCE 24 healthy individuals from endemic area No treatment 
NCE 25 healthy individuals from endemic area No treatment 
NCE 26 healthy individuals from endemic area No treatment 
NCE 27 healthy individuals from endemic area No treatment 
NCE 29 healthy individuals from endemic area No treatment 
NCE 30 healthy individuals from endemic area No treatment 
P02 healthy individuals from endemic area No treatment 
P03 healthy individuals from endemic area No treatment 
P04 healthy individuals from endemic area No treatment 
P05 healthy individuals from endemic area No treatment 
P09 healthy individuals from endemic area No treatment 
P10 healthy individuals from endemic area No treatment 
P11 healthy individuals from endemic area No treatment 
P13 healthy individuals from endemic area No treatment 




Skin lesion for and positive parasitological 
examination by microscopy 
Hadn't started the treatment yet 
L24 
Skin lesion and positive parasitological 
examination by microscopy 
Hadn't started the treatment yet 
D. K. S. 
M. N. 
Skin lesion, positive intradermal reaction (15 mm) 
and positive parasite culture 
Hadn't started the treatment yet 
R. L. J. 
Disseminated skin lesions, positive intradermal 
reaction (12 mm) and positive parasite culture 
Hadn't started the treatment yet 
T. R. 
Disseminated skin lesions, positive intradermal 
reaction (21x26 mm) and positive parasite culture 
Hadn't started the treatment yet 
O. G. T. 
Skin lesion (1.5 cm), positive intradermal reaction 
(13x19 mm) and positive parasite culture 







At the moment of the blood 
collection, the patient was... 
Group 
CL1 
W. A. B. 
Skin lesion, positive intradermal reaction (12x13 
mm) and positive parasite culture 
Hadn't started the treatment yet 
J. V. V. 
Disseminated skin lesions for 9 months and 
positive parasite culture 
Hadn't started the treatment yet 
J. P. S. Positive parasite culture Hadn't started the treatment yet 
A. O. G. 
Positive intradermal reaction (21x24 mm) and 
positive parasite culture 
Hadn't started the treatment yet 
A. R. S. 
Positive intradermal reaction (26x32 mm) and 
positive parasite culture 
Hadn't started the treatment yet 
M. L. C. Skin lesion and positive parasite culture Hadn't started the treatment yet 
P07 Skin lesion and positive intradermal reaction Hadn't started the treatment yet 




Skin lesion and positive parasitological 
examination by microscopy 
Under treatment  
L02 
Skin lesion and positive parasitological 
examination by microscopy 
Under treatment  
L05 
Skin lesion and positive parasitological 
examination by microscopy 
Under treatment  
L08 
Skin lesion and positive parasitological 
examination by microscopy 
Under treatment  
L09 
Skin lesion and positive parasitological 
examination by microscopy 
Under treatment  
P01 Skin lesion and positive intradermal reaction Under treatment  
P06 Skin lesion and positive intradermal reaction Treatment had been interrupted by 
patient. Active lesion still remained 
P08 Skin lesion and positive intradermal reaction Treatment had been interrupted by 
patient. Active lesion still remained 




Skin lesion and positive parasitological 
examination by microscopy 
Under observation during 3 months 
L04 
Skin lesion and positive parasitological 
examination by microscopy 
Under observation during 3 months 
L06 
Skin lesion and positive parasitological 
examination by microscopy 
Under observation during 3 months 
L10 
Skin lesion and positive parasitological 
examination by microscopy 
Under observation during 3 months 
L11 
Skin lesion and positive parasitological 
examination by microscopy 
Treatment had finished 
L12 
Skin lesion and positive parasitological 
examination by microscopy 
Under observation during 3 months 
L13 
Skin lesion and positive parasitological 
examination by microscopy 
Under observation during 3 months 
L15 
Skin lesion and positive parasitological 
examination by microscopy 
Under observation during 3 months 
L16 
Skin lesion and positive parasitological 
examination by microscopy 
Under observation during 3 months 
L19 
Skin lesion and positive parasitological 
examination by microscopy 







At the moment of the blood 




Skin lesion and positive parasitological 
examination by microscopy 
Under observation during 3 months 
L22 
Skin lesion and positive parasitological 
examination by microscopy 
Under observation during 3 months 
L23 
Skin lesion and positive parasitological 
examination by microscopy 
Under observation during 3 months 
P12 Skin lesion and positive intradermal reaction Under observation during 3 months 
Group 
OD 
AD 02 Positive for Syphilis No treatment 
AD 03 Positive for Syphilis No treatment 
AD 04 Positive for Syphilis No treatment 
AD 05 Positive for Syphilis No treatment 
AD 06 Positive for Syphilis No treatment 
AD 07 Positive for Syphilis No treatment 
AD 08 Positive for Syphilis No treatment 
AD 09 Positive for Syphilis No treatment 
AD 10 Positive for Hepatitis B  No treatment 
AD 11 Positive for Hepatitis B  No treatment 
AD 12 Positive for Hepatitis B  No treatment 
AD 13 Positive for Hepatitis B  No treatment 
AD 14 Positive for Hepatitis B No treatment 
AD 15 Positive for Hepatitis B  No treatment 
AD 16 Positive for Hepatitis B No treatment 
AD 17 Positive for Hepatitis B  No treatment 
AD 18 Positive for Hepatitis C No treatment 
AD 19 Positive for Hepatitis C No treatment 
AD 20 Positive for Hepatitis C No treatment 
AD 21 Positive for Hepatitis C No treatment 
AD 22 Positive for Hepatitis C No treatment 
AD 23 Positive for Hepatitis C No treatment 
AD 24 Positive for Hepatitis C No treatment 
AD 25 Positive for Hepatitis C No treatment 
01 
Positive for bacilloscopy and/or M. tuberculosis 
culture and tuberculin skin reaction ≥ 5 mm 
Treatment for Tuberculosis 
02 
Positive for bacilloscopy and/or M. tuberculosis 
culture and tuberculin skin reaction ≥ 5 mm 
Treatment for Tuberculosis 
03 
Positive for bacilloscopy and/or M. tuberculosis 
culture and tuberculin skin reaction ≥ 5 mm 
Treatment for Tuberculosis 
04 
Positive for bacilloscopy and/or M. tuberculosis 
culture and tuberculin skin reaction ≥ 5 mm 
Treatment for Tuberculosis 
05 
Positive for bacilloscopy and/or M. tuberculosis 
culture and tuberculin skin reaction ≥ 5 mm 
Treatment for Tuberculosis 
06 
Positive for bacilloscopy and/or M. tuberculosis 
culture and tuberculin skin reaction ≥ 5 mm 
Treatment for Tuberculosis 
07 
Positive for bacilloscopy and/or M. tuberculosis 
culture and tuberculin skin reaction ≥ 5 mm 







At the moment of the blood 




Positive for bacilloscopy and/or M. tuberculosis 
culture and tuberculin skin reaction ≥ 5 mm 
Treatment for Tuberculosis 
09 
Positive for bacilloscopy and/or M. tuberculosis 
culture and tuberculin skin reaction ≥ 5 mm 
Treatment for Tuberculosis 
10 
Positive for bacilloscopy and/or M. tuberculosis 
culture and tuberculin skin reaction ≥ 5 mm 
Treatment for Tuberculosis 
11 
Positive for bacilloscopy and/or M. tuberculosis 
culture and tuberculin skin reaction ≥ 5 mm 
Treatment for Tuberculosis 
12 
Positive for bacilloscopy and/or M. tuberculosis 
culture and tuberculin skin reaction ≥ 5 mm 
Treatment for Tuberculosis 
13 
Positive for bacilloscopy and/or M. tuberculosis 
culture and tuberculin skin reaction ≥ 5 mm 
Treatment for Tuberculosis 
14 
Positive for bacilloscopy and/or M. tuberculosis 
culture and tuberculin skin reaction ≥ 5 mm 
Treatment for Tuberculosis 
15 
Positive for bacilloscopy and/or M. tuberculosis 
culture and tuberculin skin reaction ≥ 5 mm 
Treatment for Tuberculosis 
16 
Positive for bacilloscopy and/or M. tuberculosis 
culture and tuberculin skin reaction ≥ 5 mm 
Treatment for Tuberculosis 
17 
Positive for bacilloscopy and/or M. tuberculosis 
culture and tuberculin skin reaction ≥ 5 mm 
Treatment for Tuberculosis 
18 
Positive for bacilloscopy and/or M. tuberculosis 
culture and tuberculin skin reaction ≥ 5 mm 
Treatment for Tuberculosis 
19 
Positive for bacilloscopy and/or M. tuberculosis 
culture and tuberculin skin reaction ≥ 5 mm 
Treatment for Tuberculosis 
20 
Positive for bacilloscopy and/or M. tuberculosis 
culture and tuberculin skin reaction ≥ 5 mm 
Treatment for Tuberculosis 
21 
Positive for bacilloscopy and/or M. tuberculosis 
culture and tuberculin skin reaction ≥ 5 mm 
Treatment for Tuberculosis 
22 
Positive for bacilloscopy and/or M. tuberculosis 
culture and tuberculin skin reaction ≥ 5 mm 
Treatment for Tuberculosis 
23 
Positive for bacilloscopy and/or M. tuberculosis 
culture and tuberculin skin reaction ≥ 5 mm 
Treatment for Tuberculosis 
24 
Positive for bacilloscopy and/or M. tuberculosis 
culture and tuberculin skin reaction ≥ 5 mm 
Treatment for Tuberculosis 
25 
Positive for bacilloscopy and/or M. tuberculosis 
culture and tuberculin skin reaction ≥ 5 mm 
Treatment for Tuberculosis 
26 
Positive for bacilloscopy and/or M. tuberculosis 
culture and tuberculin skin reaction ≥ 5 mm 
Treatment for Tuberculosis 
27 
Positive for bacilloscopy and/or M. tuberculosis 
culture and tuberculin skin reaction ≥ 5 mm 
Treatment for Tuberculosis 
28 
Positive for bacilloscopy and/or M. tuberculosis 
culture and tuberculin skin reaction ≥ 5 mm 
Treatment for Tuberculosis 
29 
Positive for bacilloscopy and/or M. tuberculosis 
culture and tuberculin skin reaction ≥ 5 mm 
Treatment for Tuberculosis 
30 
Positive for bacilloscopy and/or M. tuberculosis 
culture and tuberculin skin reaction ≥ 5 mm 
Treatment for Tuberculosis 
Group 
CD 
AD 26 Positive for Chagas disease No treatment 
AD 27 Positive for Chagas disease No treatment 
AD 28 Positive for Chagas disease No treatment 
AD 29 Positive for Chagas disease No treatment 





Table 2. Odds ratio for all antigens and diseases, considering H1 and CL1 groups as truly negative and positive 486 
groups, respectively. The p values with an asterisk show a significant difference between groups (p<0.05). NGP 487 
2334: Galα1-3Galβ1-4GlcNAc-HAS, NGP 2333: Galα1-3Galβ1-3GlcNAc-HAS, NGP 2203: Galα1-3Gal-HAS, 488 
NGP 02040: β1-4-Galactosyl-Galactose-BSA. 489 
 490 
 
Leishmaniasis Chagas Disease Other Diseases 
NGP 2334 77.31 (13.50-752.64) 84.84 (6.95-8263.79) 0.63 (0.08-4.55)* 
NGP 2333 3483.61 (81.96-348014.7) 76385.64 (88.63-3.013784e+10) 2.17 (0.06-92.72)* 
NGP 2203 1461.41 (41.97-148004.3) 133490.7 (21.39-1.771938e+12) 9.09 (0.61-342.99)* 











Table 3. Kruskal-Wallis statistical analyses of levels of anti-α-Gal antibodies found in individuals from 493 
Cutaneous Leishmaniasis endemic and non-endemic areas. The p values with an asterisk show a significant 494 
difference between groups (p<0.05). NGP 2334: Galα1-3Galβ1-4GlcNAc-HAS, NGP 2333: Galα1-3Galβ1-495 
3GlcNAc-HAS, NGP 2203: Galα1-3Gal-HAS, N.C.: β1-4-Galactosyl-Galactose-BSA (NGP 02040), P.C.: 496 
soluble proteins from crude extract from Leishmania (Viannia) braziliensis culture (strain 497 
MHOM/BR/84/LTB300), H1: healthy individuals from non-endemic areas, H2: healthy individuals from 498 
endemic areas, CL1: CL patients with active lesions and no treatment, CL2: CL patients with active lesions 499 
under the treatment, CL3: CL patients that had finished treatment and were under observation for the subsequent 500 
3 months, OD: serum reagent patients for other diseases – such as Hepatitis B and C, Syphilis and truly positive 501 
patients for Tuberculosis, CD: serum reagent patients for Chagas disease.  502 
 503 
   
p values 
 
Groups Positivity (%) H2 CL1 CL2 CL3 OD CD 
NGP 2334 
H1 21.7 >0.9999 0.2477 0.0032* <0.0001* >0.9999 0.0496* 
H2 51.4 
 
>0.9999 0.0645 0.0073* 0.3576 0.6020 
CL1 75.0 
  
>0.9999 >0.9999 0.0625 >0.9999 
CL2 100.0 
   
>0.9999 0.0008* >0.9999 
CL3 100.0 
    
<0.0001* >0.9999 
OD 37.0 
     
0.0190* 
CD 100.0 
      
NGP 2333 
H1 34.8 >0.9999 0.1806 0.0201* 0.0005* >0.9999 0.0071* 
H2 27.0 
 
0.0375* 0.0059* <0.0001* >0.9999 0.0018* 
CL1 83.3 
  
>0.9999 >0.9999 0.1294 >0.9999 
CL2 100.0 
   
>0.9999 0.0167* >0.9999 
CL3 100.0 
    
0.0001* >0.9999 
OD 35.2 
     
0.0055* 
CD 100.0 




   
p values 
 
Groups Positivity (%) H2 CL1 CL2 CL3 OD CD 
NGP 2203 
H1 34.8 >0.9999 0.0205* 0.0089* 0.0004* >0.9999 0.0037* 
H2 54.1 
 
0.1769 0.0525 0.0047* >0.9999 0.0237* 
CL1 91.7 
  
>0.9999 >0.9999 0.1571 >0.9999 
CL2 100.0 
   
>0.9999 0.0504 >0.9999 
CL3 92.3 
    
0.0033* >0.9999 
OD 46.3 
     
0.0223* 
CD 100.0 
      
N.C. 
H1 26.1 >0.9999 0.1310 0.2780 >0.9999 >0.9999 >0.9999 
H2 37.8   0.0547 0.1843 >0.9999 >0.9999 0.9806 
CL1 75.0     >0.9999 >0.9999 0.4284 >0.9999 
CL2 100.0       >0.9999 0.7235 >0.9999 
CL3 53.8         >0.9999 >0.9999 
OD 44.4           >0.9999 
CD 60.0             
P.C. 
H1 17.4 >0.9999 0.0004* 0.0545 0.1902 >0.9999 0.0113* 
H2 16.2   <0.0001* 0.0099* 0.0160* 0.2131 0.0016* 
CL1 91.7     >0.9999 >0.9999 0.0063* >0.9999 
CL2 80.0       >0.9999 0.3525 >0.9999 
CL3 61.5         >0.9999 >0.9999 
OD 40.7           0.0871 























Table 4. Mann-Whitney statistical analysis between groups of individuals from CL endemic and non-endemic 525 
areas and α-Gal antigens. The p values with an asterisk show a significant difference between groups (p<0.05). 526 
NGP 2334: Galα1-3Galβ1-4GlcNAc-HAS, NGP 2333: Galα1-3Galβ1-3GlcNAc-HAS, NGP 2203: Galα1-3Gal-527 
HAS, NGP 0204: β1-4-Galactosyl-Galactose-BSA, L. braziliensis: soluble proteins from crude extract from 528 
Leishmania (Viannia) braziliensis culture (strain MHOM/BR/84/LTB300), H1: healthy individuals from non-529 
endemic areas, H2: healthy individuals from endemic areas, CL1: CL patients with active lesions and no 530 
treatment, CL2: CL patients with active lesions under the treatment, CL3: CL patients that had finished 531 
treatment and were under observation for the subsequent 3 months, OD: serum reagent patients for other 532 
diseases – such as Hepatitis B and C, Syphilis and truly positive patients for Tuberculosis, CD: serum reagent 533 





Antigen L. braziliensis  NGP 0204 
H1 
NGP2334 0.0082* 0.0002* 
NGP 2333 0.4167 0.0299* 
NGP 2203 0.2921 0.0127* 
H2 
NGP2334 <0.0001* <0.0001* 
NGP 2333 0.3025 0.1682 
NGP 2203 0.0010* 0.0031* 
CL1 
NGP2334 0.7430 0.0045* 
NGP 2333 0.1584 0.0679 
NGP 2203 0.4704 0.0100* 
CL2 
NGP2334 0.0079* 0.0159* 
NGP 2333 0.4127 0.2222 
NGP 2203 0.4127 0.0952 
CL3 
NGP2334 <0.0001* <0.0001* 
NGP 2333 0.0101* <0.0001* 
NGP 2203 0.0337* <0.0001* 
OD 
NGP2334 0.2954 0.0121* 
NGP 2333 0.6829 0.0514 
NGP 2203 0.1497 0.0002* 
CD 
NGP2334 0.2222 0.0079* 
NGP 2333 0.3095 0.0079* 











Figure 1. ROC curve analysis and sensitivity and specificity for NGP 2334, NGP 2333, NGP 2203 and NGP 544 
0204 antigens compared to the ROC curve analysis for the positive control (L. braziliensis) for CL, Chagas 545 
disease and other diseases, performed using R software with auxiliary pROC system.  NGP 2334: Galα1-546 
3Galβ1-4GlcNAc-HAS, NGP 2333: Galα1-3Galβ1-3GlcNAc-HAS, NGP 2203: Galα1-3Gal-HAS, NGP 0204: 547 
β1-4-Galactosyl-Galactose-BSA, L. braziliensis: soluble proteins from crude extract from Leishmania (Viannia) 548 
braziliensis culture (strain MHOM/BR/84/LTB300), (A) NGP 2334 for CL, (B) NGP2333 for CL, (C) NGP2203 549 
for CL, (D) - NGP0204 for CL, (E) L. braziliensis crude extract, (F) NGP2334 for Chagas disease, (G) NGP2333 for 550 
Chagas disease , (H) NGP2203 for Chagas disease, (I) NGP0204 for Chagas disease, (J) L. braziliensis crude extract 551 
for Chagas disease, (K) NGP2334 for other disease, (L) NGP2333 for other disease, (M) NGP2203 for other disease, 552 





Figure 2. Levels of anti-α-Gal antibodies detected in individuals from CL endemic and non-endemic areas in 556 
Brazil after cleavage specific with α-galactosidase enzyme from Green Coffee beans on α-galactosylated NGPs 557 
antigen. NGP 2334: Galα1-3Galβ1-4GlcNAc-HAS, NGP 2333: Galα1-3Galβ1-3GlcNAc-HAS, NGP 2203: 558 
Galα1-3Gal-HAS, H1: healthy individuals from non-endemic areas, H2: healthy individuals from endemic 559 
areas, CL1: CL patients with active lesions and no treatment, CL2: CL patients with active lesions under the 560 
treatment, CL3: CL patients that had finished treatment and were under observation for the subsequent 3 561 
months. 562 
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